Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab

被引：14
|
作者：
Tejpar, S.
Bokemeyer, C.
Celik, I.
Schlichting, M.
Sartorius, U.
Van Cutsem, E.
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3511
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With KRas Wild-Type Tumours in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S264 - S264
  • [42] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
    Bokemeyer, Carsten
    Bondarenko, Igor
    Makhson, Anatoly
    Hartmann, Joerg T.
    Aparicio, Jorge
    de Braud, Filippo
    Donea, Serban
    Ludwig, Heinz
    Schuch, Gunter
    Stroh, Christopher
    Loos, Anja H.
    Zubel, Angela
    Koralewski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 663 - 671
  • [43] Cetuximab observational study as first-line therapy in patients with metastatic colorectal cancer
    Itabashi, Michio
    Tani, Kimitaka
    Muro, Kei
    Masuishi, Toshiki
    Ohashi, Yasuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] INFLUENCE OF BRAF V600E AND DIFFERENT KRAS MUTATIONS ON OUTCOME OF METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST- LINE THERAPY
    Rebersek, Martina
    Boc, Marko
    Hlebanja, Zvezdana
    Volk, Neva
    Benedik, Jernej
    Ebert, Maja
    Mesti, Tanja
    Ocvirk, Janja
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [45] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [46] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [47] Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer Two case reports
    Okada, Satoshi
    Hata, Keisuke
    Kawai, Kazushige
    Yamamoto, Yoko
    Tanaka, Toshiaki
    Nishikawa, Takeshi
    Sasaki, Kazuhito
    Kaneko, Manabu
    Emoto, Shigenobu
    Murono, Koji
    Nozawa, Hiroaki
    MEDICINE, 2019, 98 (12)
  • [48] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Randomized phase II study of cetuximab vs. irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study): Compared with ICECREAM study
    Keiichiro, Ishibashi
    Masato, Nakamura
    Akihito, Tsuji
    Yasutaka, Takinishi
    Yoshiaki, Shindo
    Toru, Aoyama
    Junichi, Sakamoto
    Koji, Oba
    Hideyuki, Mishima
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet plus Bevacizumab
    Giampieri, Riccardo
    Lupi, Alessio
    Ziranu, Pina
    Bittoni, Alessandro
    Pretta, Andrea
    Pecci, Federica
    Persano, Mara
    Giglio, Enrica
    Copparoni, Cecilia
    Crocetti, Sonia
    Mandolesi, Alessandra
    Faa, Gavino
    Coni, Pierpaolo
    Scartozzi, Mario
    Berardi, Rossana
    FRONTIERS IN ONCOLOGY, 2021, 11
12345